T
ASND icon

TOBAM’s Ascendis Pharma A/S ASND Stock Holding History

TOBAM’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,622
Closed -$223K – 257
2024
Q4 		$223K Sell
1,622
-541
-25% -$71.1K 0.07% 151
2024
Q3 		$323K Hold
2,163
– – 0.06% 156
2024
Q2 		$295K Hold
2,163
– – 0.05% 155
2024
Q1 		$327K Buy
2,163
+630
+41% +$89.9K 0.03% 176
2023
Q4 		$193K Sell
1,533
-277
-15% -$27.6K 0.02% 226
2023
Q3 		$169K Hold
1,810
– – 0.01% 244
2023
Q2 		$162K Hold
1,810
– – 0.01% 273
2023
Q1 		$194K Sell
1,810
-718
-28% -$82.1K 0.01% 223
2022
Q4 		$309K Buy
2,528
+526
+26% +$61.1K 0.02% 174
2022
Q3 		$207K Buy
2,002
+564
+39% +$53.5K 0.01% 210
2022
Q2 		$134K Buy
1,438
+1,217
+551% +$115K 0.01% 277
2022
Q1 		$26K Sell
221
-883
-80% -$102K ﹤0.01% 416
2021
Q4 		$149K Sell
1,104
-1,816
-62% -$270K 0.01% 211
2021
Q3 		$465K Sell
2,920
-1,149
-28% -$157K 0.02% 149
2021
Q2 		$535K Buy
4,069
+907
+29% +$121K 0.02% 148
2021
Q1 		$408K Buy
3,162
+828
+35% +$126K 0.02% 153
2020
Q4 		$389K Sell
2,334
-117
-5% -$19.3K 0.02% 155
2020
Q3 		$378K Buy
2,451
+202
+9% +$29K 0.02% 143
2020
Q2 		$333K Buy
2,249
+558
+33% +$76.6K 0.02% 112
2020
Q1 		$190K Sell
1,691
-96
-5% -$12.5K 0.02% 122
2019
Q4 		$249K Sell
1,787
-23
-1% -$2.56K 0.02% 103
2019
Q3 		$174K Buy
1,810
+446
+33% +$49.8K 0.01% 101
2019
Q2 		$157K Buy
+1,364
New +$163K 0.01% 102

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TOBAM's ASND Position: Q1 2025 in Review

TOBAM sold out of Ascendis Pharma A/S (ASND) in Q1 2025, closing a stake of 1,622 shares — an estimated $223K sold.

TOBAM first reported a position in ASND in Q2 2019 and held it in 23 quarters. The position peaked at $535K in Q2 2021. 244 funds tracked by Wall St. Rank hold ASND as of Q1 2025.

  • TOBAM reported no remaining Ascendis Pharma A/S position as of Q1 2025 after selling out during the quarter.
  • TOBAM sold 1,622 Ascendis Pharma A/S shares in Q1 2025, an estimated $223K.
  • TOBAM first reported a position in Ascendis Pharma A/S in Q2 2019 and held it in 23 quarters.
  • TOBAM's Ascendis Pharma A/S position peaked at $535K in Q2 2021.
  • 244 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2025.

Based on TOBAM's 13F filing for Q1 2025, filed 16 Apr 2025.